Summary of Onxeo’s Liquidity Contract With Kepler Cheuvreux

Regulatory News:

Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) shares, the following resources were listed in the liquidity account as at June 30, 2020, settlement date:

• 199,994 shares
• €150,846.71 in cash

During the 1^st half of 2020, were negotiated a total of:

BUY	861,697 shares	€551,206.32	783 executions
SALE	1,002,772 shares	€688,199.73	1,052 executions

It is recalled that for the last half-year summary as at December 31, 2019, the following resources were included in the liquidity account:

• 341,069 shares
• €13,897.05 in cash

During the 2^nd half of 2019, were negotiated a total of:

BUY	510,522 shares	€327,615.49	656 executions
SALE	380,311 shares	€246,522.48	525 executions

It is also recalled that when the contract was set up, the following resources had been allocated to the liquidity account:

• 87,612 shares
• €196,423.24 in cash

The liquidity agreement complies with AMF Decision n° 2018-01 dated 2^nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA, the first compound from platON, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments. Preliminary results from the first cohort with carboplatin alone showed good tolerability, stabilization of the disease and an increase in the duration of treatment compared to previous treatments.

OX401 is a new drug candidate from platON, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

For further information, please visit www.onxeo.com.

Forward looking statements
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to chapter 3 “Risk Factors” ("Facteurs de Risque") of the Company’s universal registration document filed with the Autorité des marchés financiers on April 27, 2020 under number D.20-0362, which is available on the websites of the Autorité des marchés financiers (www.amf-france.org) an the Company (www.onxeo.com).

A Public Limited Company with Share Capital of 12,683,913.25 euros
Registered Address 49, boulevard du Général Martial Valin – 75015 Paris
Paris Trade and Companies’ Register 410 910 095

APPENDIX

	Buy Side				Sell-Side
	Number of executions	Number of shares	Traded volume in EUR		Number of executions	Number of shares		Traded volume in EUR
Total	783	861,697	551,206.32		1,052	1,002,772		688,199.73
2/1/2020	15	10,058	5,330.74		9	6,684		3,676.20
3/1/2020	1	1,000	540.00		1	1,000		550.00
6/1/2020	3	2,000	1,080.00		-	-		-
7/1/2020	6	4,001	2,120.53		1	1		0.54
8/1/2020	-	-	-		13	6,000		3,300.00
9/1/2020	13	12,000	6,480.00		17	12,316		6,896.96
10/1/2020	1	1	0.56		68	52,510		32,031.10
13/01/2020	8	7,000	4,340.00		16	12,000		7,800.00
14/01/2020	26	18,001	10,620.59		1	1		0.62
15/01/2020	-	-	-		8	6,192		3,839.04
16/01/2020	9	7,000	4,270.00		6	9,808		6,179.04
17/01/2020	1	1	0.62		1	1		0.62
20/01/2020	24	20,031	11,818.29		-	-		-
21/01/2020	-	-	-		7	4,076		2,486.36
22/01/2020	10	8,468	4,911.44		2	2,924		1,783.64
23/01/2020	7	3,501	1,995.57		-	-		-
24/01/2020	19	16,000	8,960.00		2	2,000		1,140.00
27/01/2020	21	16,000	8,640.00		-	-		-
28/01/2020	-	-	-		20	7,000		3,920.00
29/01/2020	9	8,000	4,480.00		25	18,257		10,406.49
30/01/2020	-	-	-		39	29,743		17,548.37
31/01/2020	35	31,352	17,870.64		1	1,000		590.00
3/2/2020	11	8,648	4,669.92		5	3,001		1,680.56
5/2/2020	-	-	-		3	2,089		1,169.84
6/2/2020	-	-	-		5	3,911		2,229.27
7/2/2020	2	1,000	550.00		-	-		-
10/2/2020	1	1,000	550.00		-	-		-
11/2/2020	4	4,000	2,200.00		-	-		-
12/2/2020	6	6,000	3,240.00		1	1,000		550.00
13/02/2020	18	13,001	7,280.56		39	37,000		21,460.00
17/02/2020	8	6,000	3,300.00		4	3,000		1,680.00
19/02/2020	4	2,000	1,100.00		-	-		-
21/02/2020	2	2,000	1,100.00		-	-		-
24/02/2020	30	23,942	12,689.26		-	-		-
25/02/2020	5	4,000	2,080.00		7	6,000		3,240.00
26/02/2020	6	5,000	2,550.00		-	-		-
27/02/2020	14	9,197	4,782.44		10	7,000		3,780.00
28/02/2020	20	13,836	6,918.00		9	6,707		3,420.57
2/3/2020	8	4,122	2,019.78		8	6,293		3,272.36
3/3/2020	2	2,000	1,000.00		13	7,300		3,869.00
4/3/2020	9	6,000	3,120.00		7	5,700		3,021.00
5/3/2020	12	11,000	5,500.00		1	3,000		1,560.00
6/3/2020	6	4,000	1,960.00		-	-		-
9/3/2020	16	13,845	5,953.35		2	2,000		920.00
11/3/2020	2	1,000	410.00		-	-		-
12/3/2020	5	3,200	1,248.00		-	-		-
13/03/2020	1	100	35.00		1	100		38.00
16/03/2020	5	500	165.00		-	-		-
17/03/2020	3	300	96.00		4	400		140.00
18/03/2020	-	-	-		1	100		35.00
19/03/2020	-	-	-		3	300		111.00
23/03/2020	2	200	74.00		2	200		80.00
24/03/2020	-	-	-			100		38.00
25/03/2020	5	3,000	1,200.00			6,100		2,562.00
26/03/2020	2	2,000	800.00			1,000		410.00
27/03/2020	3	3,000	1,200.00			3,000		1,260.00
30/03/2020	1	1,000	400.00			1,000		430.00
31/03/2020	-	-	-			3,000		1,320.00
1/4/2020	1	1,000	420.00			-		-
2/4/2020	1	1	0.44			825		379.50
7/4/2020	8	6,000	2,760.00			8,176		3,924.48
9/4/2020	-	-	-			2,000		960.00
14/04/2020	2	2,000	960.00			5,000		2,450.00
15/04/2020	28	19,410	10,287.30			56,000		30,800.00
16/04/2020	7	3,590	1,902.70			1,889		1,095.62
17/04/2020	24	24,000	13,920.00			31,111		18,666.60
20/04/2020	46	38,000	20,140.00			5,815		3,140.10
21/04/2020	3	3,000	1,500.00			2,000		1,040.00
22/04/2020	5	4,000	2,000.00			-		-
23/04/2020	5	5,000	2,450.00			1,000		510.00
24/04/2020	5	4,189	1,968.83			-		-
27/04/2020	3	2,000	980.00			7,000		3,570.00
28/04/2020	-	-	-			6,000		3,120.00
29/04/2020	1	1,000	510.00			5,000		2,650.00
30/04/2020	11	10,000	5,000.00			-		-
4/5/2020	2	2,000	960.00			1,000		500.00
5/5/2020	-	-	-			20,185		10,899.90
6/5/2020	10	8,000	4,160.00			-		-
7/5/2020	5	4,337	2,211.87			-		-
8/5/2020	7	4,364	2,182.00			1		0.51
12/5/2020	10	8,300	4,316.00			15,679		8,309.87
13/05/2020	10	9,000	4,500.00			1		0.53
14/05/2020	5	5,000	2,400.00			-		-
18/05/2020	-	-	-			2,000		980
19/05/2020	-	-	-			2,000		1,000.00
20/05/2020	1	1,000	500.00			10,000		5,200.00
21/05/2020	3	2,000	980.00			-		-
22/05/2020	-	-	-			3,000		1,470.00
25/05/2020	1	1,000	490.00			-		-
26/05/2020	4	3,000	1,470.00			-		-
27/05/2020	-	-	-			161,119		109,560.92
28/05/2020	24	54,000	44,820.00			63,000		56,700.00
29/05/2020	22	50,000	42,500.00			90,000		81,900.00
1/6/2020	3	15,000	12,150.00			20,000		17,600.00
2/6/2020	14	29,139	23,602.59			4,472		3,845.92
3/6/2020	7	20,861	15,854.36			528		411.84
4/6/2020	5	20,000	15,800.00			40,000		32,800.00
5/6/2020	5	10,000	7,800.00			-		-
8/6/2020	2	5,000	3,800.00			537		429.60
9/6/2020	1	5,000	3,800.00			5,000		3,950.00
10/6/2020	6	5,000	3,750.00			-		-
11/6/2020	12	20,000	14,600.00			-		-
12/6/2020	6	19,510	13,461.90			-		-
15/06/2020	6	10,829	7,255.43			-		-
16/06/2020	5	5,194	3,791.62			47,006		35,254.50
17/06/2020	3	11,667	8,400.24			-		-
19/06/2020	2	5,000	3,800.00			24,463		18,836.51
22/06/2020	-	-	-			50,000		42,000.00
23/06/2020	11	30,000	23,700.00			-		-
24/06/2020	6	30,000	22,500.00			-		-
25/06/2020	7	10,000	7,800.00			30,000		23,700.00
26/06/2020	6	15,000	11,400.00			-		-
29/06/2020	-	-	-			150		117.00
30/06/2020	1	1	0.75			1		0.75

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20200703005107/en/